Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + Radiotherapy Prior to Surgery for HPV- HNSCC
NCT03635164Phase 1Completed
- Sponsor
- University of Colorado Denver
- Start
- Nov 2018
- Primary completion
- Nov 2021
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of durvalumab in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Colorado Denver. Primary endpoints: Maximum Tolerated Dose at 24 months and Dose Limiting Toxicities at 24 months. Started Nov 2018; status: completed.
02
Drugs
durvalumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03635164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03635164.